Accordingly, ICD-inducing chemotherapeutics have been incorporated into established treatment protocols to improve their efficacy, notably in the context of immunotherapy with immune checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1.2 In addition, it has been reported in some clinical trials that ICD-associated DAMPs assessed in the blood or in tumor biopsies from patients could serve as predictive and prognostic markers. The gene discussed is CD274; the disease is neoplasm.